Urticaria Management Guidelines

Introduction to Urticaria Treatment

The American Academy of Allergy, Asthma, and Immunology recommends second-generation H1 antihistamines (cetirizine, loratadine, desloratadine, fexofenadine, levocetirizine) at standard doses for 2-4 weeks as the foundation of urticaria treatment 1
If inadequate response after 2-4 weeks, increasing the antihistamine dose up to 4 times the standard dose is recommended before considering corticosteroids 1
More than 40% of patients respond to antihistamines alone, and approximately 75% respond to dose escalation 1

For acute severe urticaria, prednisolone 50 mg daily for 3 days is the recommended regimen, not methylprednisolone 1, 2
Lower doses of corticosteroids are frequently effective and should be considered to minimize exposure 1, 2
Short courses of 3-10 days maximum are appropriate for severe acute exacerbations 1, 2
Doses of 40-80 mg daily of methylprednisolone have been reported in retrospective studies for other conditions, but prednisolone is preferred for urticaria 3, 4

Long-term oral corticosteroids should not be used in chronic urticaria except in very selected cases under regular specialist supervision (Strength of recommendation A) 1, 2
Chronic corticosteroids are contraindicated in chronic spontaneous urticaria due to cumulative toxicity and unfavorable risk-benefit ratio 1, 2

Start with second-generation H1 antihistamine at standard dose for 2-4 weeks 1
Increase antihistamine up to 4 times standard dose if inadequate control 1
Add prednisolone 50 mg daily for 3 days if severe acute urticaria persists despite antihistamines 1, 2
Consider lower doses of corticosteroids to minimize exposure 1, 2

Add H2 antihistamines (ranitidine or famotidine) for refractory chronic urticaria 1
Consider leukotriene receptor antagonists (montelukast) for refractory chronic urticaria 1
Omalizumab 300 mg subcutaneously every 4 weeks is effective for antihistamine-refractory chronic urticaria 1
Cyclosporine 4 mg/kg daily is effective in approximately two-thirds of severe autoimmune urticaria cases 1

Never use corticosteroids as first-line treatment when antihistamines are sufficient 1
Never continue corticosteroids beyond 3-10 days due to cumulative toxicity 1, 2
Never use chronic corticosteroids for chronic spontaneous urticaria 1, 2
Avoid aspirin and NSAIDs in patients with urticaria, as they can exacerbate symptoms 1
Do not use first-generation antihistamines as first-line monotherapy due to sedating properties 5

Administer epinephrine 0.5 mL of 1:1000 (500 µg) intramuscularly immediately for anaphylaxis or severe laryngeal angioedema 1

Children with long‑COVID are significantly more likely to have had chronic urticaria and allergic rhinitis before infection, indicating these conditions are recognized manifestations of post‑COVID disease. 6, 7

The underlying mechanisms are thought to involve immune dysregulation, autoimmunity through molecular mimicry, and activation of mast‑cell pathways; these processes are markedly more severe in patients with long‑COVID compared with pre‑COVID controls. 8, 7

Histamine‑receptor antagonists (second‑generation H1‑antihistamines) produce clinical improvement in the majority of children with long‑COVID‑related mast‑cell activation syndrome symptoms. 8, 7

Both the number of MCAS symptoms and their severity are substantially higher in children with long‑COVID than in pre‑COVID or healthy control groups. 8, 7